Phase I trial with AP 301 for the treatment of pulmonary oedema
Latest Information Update: 07 Jan 2014
Price :
$35 *
At a glance
- Drugs Solnatide (Primary)
- Indications Acute lung injury; Pulmonary oedema; Reperfusion injury
- Focus Adverse reactions
- Sponsors APEPTICO Forschung und Entwicklung
- 07 Jan 2014 New trial record